2,2,4,6,6-Pentamethyl-3,6-dihydro-2H-pyran | 76935-95-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡喃
• 英文名称: 2,2,4,6,6-Pentamethyl-3,6-dihydro-2H-pyran
• 英文别名: 2,2,4,6,6-pentamethyl-3H-pyran
• CAS: 76935-95-0
• 化学式: C₁₀H₁₈O
• 分子量: 154.252
• InChiKey: MXHOMGJJQNUGLI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2,2,6,6-四甲基-2H-3,5,6-三氢吡喃-4-酮 在 碘 作用下， 生成 2,2,4,6,6-Pentamethyl-3,6-dihydro-2H-pyran
  参考文献：
  名称：

  Remane, Horst; Borsdorf, Rolf; Jaspers, Veronika, Zeitschrift fur Chemie, 1980, vol. 20, # 9, p. 345 - 346

  摘要：

  DOI：

文献信息

• INHIBITORS OF C-FMS KINASE
  申请人：Illig Carl R.

  公开号：US20090105296A1

  公开（公告）日：2009-04-23

  The invention is directed to compounds of Formula I: wherein Z, X, J, R 2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.

  该发明涉及以下式I的化合物： 其中Z、X、J、R2和W如规范中所述，以及其溶剂化合物、水合物、互变异构体和药学上可接受的盐，能够抑制蛋白酪氨酸激酶，特别是c-fms激酶。本发明还提供了治疗自身免疫疾病；以及伴有炎症成分的疾病；治疗卵巢癌、子宫癌、乳腺癌、前列腺癌、肺癌、结肠癌、胃癌、毛细胞白血病的转移；以及治疗疼痛，包括肿瘤转移或骨关节炎引起的骨骼疼痛，或内脏、炎症和神经源性疼痛；以及骨质疏松症、帕盖特病和其他骨吸收介导发病率的疾病，包括类风湿性关节炎和其他形式的炎症性关节炎、骨关节炎、假体失败、溶骨性肉瘤、骨髓瘤和肿瘤转移至骨骼的方法，其中使用了式I的化合物。
• SUBSTITUTED IMIDAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS
  申请人：Janssen Pharmaceutica NV

  公开号：US20150051225A1

  公开（公告）日：2015-02-19

  Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) as follows: wherein R 1 , R 2 , R 3 , and G are defined herein.

  揭示了用于治疗各种疾病、综合征、症状和障碍的化合物、组合物和方法，包括疼痛。这些化合物由以下的化学式（I）表示：其中R1、R2、R3和G在此处被定义。
• COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES
  申请人：BIGGART Agnes

  公开号：US20150175613A1

  公开（公告）日：2015-06-25

  The present invention provides compounds of Formula A: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as leishmaniasis, human African trypanosomiasis and Chagas disease.

  本发明提供了Formula A的化合物：或其药学上可接受的盐、互变异构体或立体异构体，其中变量如本文所定义。本发明还提供了包含这种化合物的药物组合物，并使用这种化合物治疗、预防、抑制、改善或根除由寄生虫引起的疾病的病理学和/或症状学的方法，如利什曼病、人类非洲锥虫病和光照病。
• SUBSTITUTED PYRAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS
  申请人：Janssen Pharmaceutica NV

  公开号：US20140163031A1

  公开（公告）日：2014-06-12

  The present invention relates to compounds of Formula (I), wherein X 1 , X 2 , X 3 , X 4 , R 1 , R 2 , R 3 , and Q are as defined herein, useful as N-type calcium channel blockers.

  本发明涉及式(I)的化合物，其中X1、X2、X3、X4、R1、R2、R3和Q的定义如本文所述，作为N型钙通道阻滞剂有用。
• NOVEL TRYPTOPHAN HYDROXYLASE INHIBITOR AND PHARMACEUTICAL COMPOSITION INCLUDING SAME
  申请人：Gwangju Institute of Science and Technology

  公开号：EP3674303A1

  公开（公告）日：2020-07-01

  The present invention relates to a novel tryptophan hydroxylase inhibitor and a pharmaceutical composition including same, wherein the novel tryptophan hydroxylase inhibitor has an excellent inhibitory effect on TPH1, and thus can be usefully used for the prevention or treatment of disorders, such as metabolic disorders, cancer, digestive or cardiovascular system disorders, related to TPH1 activity. In particular, the novel tryptophan hydroxylase inhibitor has an excellent treatment effect on inflammatory bowel disorders, and thus can be usefully used for the treatment of inflammatory bowel disorder.

  本发明涉及一种新型色氨酸羟化酶抑制剂和包括其在内的药物组合物，其中新型色氨酸羟化酶抑制剂对 TPH1 具有极佳的抑制作用，因此可有效用于预防或治疗与 TPH1 活性有关的疾病，如代谢紊乱、癌症、消化系统或心血管系统疾病。特别是，新型色氨酸羟化酶抑制剂对炎症性肠病有很好的治疗效果，因此可用于治疗炎症性肠病。